ArticleRevista medica del Instituto Mexicano del Seguro Social2025
[Cryptococcus albidus, Naganishia albida, primary skin infection, first case reported in Mexico].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increase in immunosuppressive treatments and diseases that affect cellular immunity, such as diabetes, renal disease, and oncological or rheumatological conditions, has led to a rise in infections caused by opportunistic microorganisms. The aim of this work is to identify Naganishia albida as an infectious pathogen in immunocompromised patients, highlighting its importance and clinical evolution. Clinical case: One of the first identified cases of Naganishia albida is reported in a patient with immunosuppression secondary to oncological treatment, with domestic activity exposure being the main risk factor. The patient had a good clinical outcome due to timely diagnosis, guided by biopsy culture and reverse stains. Conclusion: Given the increase in conditions that affect the immune system, it is crucial for physicians of any specialty to pay special attention to secondary infections caused by immunosuppression. Without appropriate treatment, these infections can become invasive, negatively impacting the prognosis and evolution of the patient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.